The Corporation has 29.81M shares outstanding and 24.47M shares were floated in market. Replimune Group, Inc. (NASDAQ:REPL) moved with change of -1.21% to $13.83 with the total traded volume of 20,486 shares in recent session versus to an average volume of 43,979. After opening the first trading session at $13.97, it registered a day’s high of $14.07 and touched a day’s low of $13.05.
Replimune Group Inc. (REPL) recently reported financial results for its fourth fiscal quarter and year ended March 31, 2019, and provided an update on its business.
Replimune stated a net loss of $6.6M for the fiscal fourth quarter, ended March 31, 2019, and a net loss of $30.8M for the fiscal year ended March 31, 2019, as contrast to a net loss of $7.1M and net loss of $19.7M for the comparable periods in the previous fiscal year, respectively. The raise in net losses for both periods were primarily Because of an raise in research and development expenses and administrative costs associated with our operations.
Research and development expenses were $5.4M for the fiscal fourth quarter of 2019, and $22.2M for the year ended March 31, 2019, as contrast to $4.5M and $13.5M for the comparable periods in the previous fiscal year, respectively. The raise in research and development expenses was primarily driven by additional costs related to Replimune’s preclinical and clinical development activities for its pipeline, as well as raised salary and related benefits costs Because of the raise in employee headcount from 44 on March 31, 2018 to 67 on March 31, 2019.
General and administrative expenses were $2.4M for the fiscal fourth quarter of 2019, and $8.8M for the year ended March 31, 2019, as contrast to $2.5M and $5.7M for the comparable periods in the previous fiscal year, respectively. The raise in general and administrative expenses was primarily Because of the raise in employee headcount and the impact of stock-based compensation in 2019.
Replimune ended the fiscal year with $134.8M in cash and cash equivalents and short-term investments, contrast with $141.8M as of December 31, 2018 and $61.6M as of March 31, 2018. The year-on-year raise reflects net proceeds received of $103.3M (net of deferred offering costs of $9.9M) in connection with the Company’s IPO in July 2018.
Based on its current operating plan, Replimune expects that its
current cash and cash equivalents and short-term investments will enable it to
fund its operating expenses and capital expenditure requirements into the
second half of calendar 2021.REPL return on assets ratio of the Company was
-25.70% and return on equity ratio was -48.90%. The stock as of last trading
session moved 55.74% up from its 52 week low and was -41.27% behind its 52 week
high. EPS growth for this year is -155.70% and EPS growth for next year is
expected to reach at 4.30%.
Allison Hickman –Health and Biotech
My name is Allison Hickman, and I am the mainstream behind the”dailynewsme.com” for the powerful and most delicate insights into the latest activities in the Investing category. I started my journey as an independent financial consultant. I had approximately 6 years of experience in this field. I am free soul so; my passion for exploring the world has taken me to the nations across the globe and given me the chance to report for a portion of the best news associations. Currently, I am a full-time editor as experienced in finance and started to use my abilities.
Address: 4427 Irish Lane
Madison, WI 53704, United States of America
Phone Number: +1 608 770 1673